<DOC>
	<DOCNO>NCT01395056</DOCNO>
	<brief_summary>To access effectiveness cyclophosphamide combine thiotepa carboplatin chemotherapy combine adoptive cellular therapy dendritic cytokine-induced killer cell triple negative metastatic breast cancer patient</brief_summary>
	<brief_title>Study Chemotherapy With Adoptive Cellular Therapy With DC-CIK Cells Triple Negative Breast Cancer Patients</brief_title>
	<detailed_description>1 . Metastatic breast cancer patient definitively diagnosis base histopathology , ER-negative PR-negative , FISH test her-2-negative 2 . All patient enrol give standard cyclophosphamide combine thiotepa carboplatin chemotherapy cellular therapy.Cellular therapy consist one cycle chemotherapy follow apheresis ex vivo culture generate DC CIK , follow low-dose Oral Cyclophosphamide . 3 . The response assess use Response Evaluation Criteria Solid Tumor Group ( RECIST ) guideline . 4 . Estimate time progression , survival rate clinical benefit response patient . 5 . Find biomarkers associate drug response .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<criteria>Failure anthracycline and/or taxol chemotherapy ; metastatic tumor histologically confirm immunohistochemical staining ERnegative PRnegative . FISH test her2negative ; Metastatic tumor remove surgery procedure ; An Eastern Cooperative Oncology Group ( ECOG ) performance status 02 ; Normal cardiac , hepatic , renal bone marrow function ; Life expectancy â‰¥3 month . Central nervous system metastasis ; Serious uncontrolled concurrent medical illness ; History malignancy ; Having enrol clinal trial within month ;</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>breast neoplasm</keyword>
	<keyword>Neoplasm Metastasis</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>